<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961608</url>
  </required_header>
  <id_info>
    <org_study_id>TACPKPD</org_study_id>
    <nct_id>NCT02961608</nct_id>
  </id_info>
  <brief_title>Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.</brief_title>
  <acronym>TACPKPD</acronym>
  <official_title>Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <brief_summary>
    <textblock>
      LCP-Tacro is an extended-release formulation of tacrolimus designed for once-daily dosing.&#xD;
      Phase 1 studies demonstrated greater bioavailability than twice-daily tacrolimus capsules and&#xD;
      no new safety concerns.&#xD;
&#xD;
        -  Stable kidney transplant patients can be safely converted from Adoport® twice-daily to&#xD;
           LCP-Tacro®.&#xD;
&#xD;
        -  The greater bioavailability of LCP-Tacro after once-daily dosing results in similar&#xD;
           (AUC) exposure, at a dose approximately 30% less, than the total daily dose of Adoport®.&#xD;
&#xD;
        -  LCP-Tacro provides a slow drug release and this results in flatter kinetics&#xD;
           characterized by significantly lower peak-trough fluctuations.&#xD;
&#xD;
        -  CN is the major cellular target of the calcineurin inhibitors (CNIs) cyclosporine A&#xD;
           (CsA) and tacrolimus. The ability of these drugs to inhibit CN activity is dependent on&#xD;
           their binding to the respective immunophilins, cyclophilins A and B for CsA and FKBP12&#xD;
           for tacrolimus.&#xD;
&#xD;
        -  CN inhibition is a rate limiting phenomenon. Over concentrations of tacrolimus does not&#xD;
           correlate with an increase in the CN activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of CN activity</measure>
    <time_frame>Baseline and 35 days post conversion</time_frame>
    <description>The main objective of this study is to compare the area under the curve (AUC) of CN activity after administration of a sustained release formulation (LCP- Tacro, Envarsus®) compared to an immediate release formulation (Prograf®) of TAC in renal transplant patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the curve 0-24 h of each TAC formulation</measure>
    <time_frame>Baseline and 35 days post conversion</time_frame>
    <description>Pharmacokinetic study AUC 0-24 h of each TAC formulation 12h (Prograf®) and the new formulation of TAC every 24h (LCP- Tacro, Envarsus®).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAC trough concentrations for optimal inhibition of CN</measure>
    <time_frame>Baseline and 35 days post conversion</time_frame>
    <description>Study PK / PD: relationship PK TAC (drug exposure) and PD (activity CN) of both formulations. Set TAC trough concentrations for optimal inhibition of CN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug exposure according to CYP3A (CYP3A4 and CYP3A5 * 22 * 3) and ABCB1 (C3435T) polymorphism.</measure>
    <time_frame>Baseline and 35 days post conversion</time_frame>
    <description>Analysis of drug exposure according to CYP3A (CYP3A4 and CYP3A5 * 22 * 3) and ABCB1 (C3435T) polymorphism.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)</intervention_name>
    <description>Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years).&#xD;
&#xD;
               -  Receivers cadaveric renal graft or living donor with more than 6 months&#xD;
                  post-transplant evolution.&#xD;
&#xD;
               -  Patients receiving Prograf stable and stable TAC trough concentrations between&#xD;
                  5-10ng / ml non-interrupted oral dose for at least 10 days (steady state&#xD;
                  conditions).&#xD;
&#xD;
               -  receiving concomitant immunosuppressive medication allowed: sodium or&#xD;
                  mycophenolate mofetil and corticosteroids.&#xD;
&#xD;
               -  Subjects must be willing to give their written informed consent to testing and be&#xD;
                  able to do consent. If a subject can not give written informed consent&#xD;
                  independently, you can do your legal representative instead.&#xD;
&#xD;
               -  Women of childbearing age must undergo a pregnancy test at the time of inclusion&#xD;
                  and accept the use of a medically acceptable method of contraception during the&#xD;
                  selection and receive medication as specified in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients on dialysis or treatment of rejection after transplantation.&#xD;
&#xD;
               -  Patients treated with substances with potential interaction with TAC,&#xD;
                  particularly potent inhibitors of CYP3A4 (such as telaprevir, boceprevir,&#xD;
                  ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin or&#xD;
                  clarithromycin) or inducers of CYP3A4 (such as rifampin or rifabutin).&#xD;
&#xD;
               -  Patients participating in another clinical trial or treated with any&#xD;
                  investigational drug within 30 days prior to inclusion.&#xD;
&#xD;
               -  Patients with liver disease.&#xD;
&#xD;
               -  The patient or donor with the current diagnosis or history of malignancy within&#xD;
                  the past 5 years except carcinoma nonmetastatic basal or squamous cell skin&#xD;
                  treated successfully.&#xD;
&#xD;
               -  pregnant or breast-feeding women and all women of childbearing age unless they&#xD;
                  use reliable contraception. A pregnancy test will be performed at screening and&#xD;
                  at the end of the study.&#xD;
&#xD;
               -  Receiver of any other organ transplanted kidney.&#xD;
&#xD;
               -  The recipients of bone marrow or stem cell transplant.&#xD;
&#xD;
               -  Recipients of a kidney from a donor ABO incompatible.&#xD;
&#xD;
               -  Patients with donor specific anti-HLA antibodies.&#xD;
&#xD;
               -  Recipients of a kidney with anticipated cold ischemia time of ≥ 24 hours.&#xD;
&#xD;
               -  Patients with concomitant uncontrolled infection, systemic infection in&#xD;
                  treatment, or any other unstable medical condition that could interfere with the&#xD;
                  study objectives.&#xD;
&#xD;
               -  Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal&#xD;
                  disorder that can affect the absorption of TAC.&#xD;
&#xD;
               -  Patients with white blood cell count ≤ 2.8 x 109 / L unless the absolute&#xD;
                  neutrophil count (ANC) is ≥ 1.0 x 109 / L&#xD;
&#xD;
               -  Patients with platelet count ≤ 50 x 109 / L&#xD;
&#xD;
               -  Patients with levels of aspartate aminotransferase (AST) or alanine&#xD;
                  aminotransferase (ALT) exceeding&gt; 3 times the upper limit of normal during the 30&#xD;
                  days prior to the transplant procedure.&#xD;
&#xD;
               -  Patients with known hypersensitivity to TAC or any of the excipients in the&#xD;
                  formulation Envarsus®.&#xD;
&#xD;
               -  unable to swallow study medication patients.&#xD;
&#xD;
               -  Patients with any form of current substance abuse, psychiatric disorder or a&#xD;
                  condition that, in the investigator's opinion, may invalidate the communication&#xD;
                  with the investigator.&#xD;
&#xD;
               -  Patients who require a high intake of potassium or potassium-sparing diuretics.&#xD;
&#xD;
               -  Patients treated with substances with known nephrotoxic or neurotoxic effects.&#xD;
&#xD;
               -  positive for hepatitis C virus (HCV-RNA positive) and / or hepatitis B virus (HBV&#xD;
                  DNA or HBsAg positive) receivers.&#xD;
&#xD;
               -  positive for human immunodeficiency virus (HIV-Ab positive) receivers.&#xD;
&#xD;
               -  unable to understand the effects and risks of the study, who can not give&#xD;
                  informed consent in writing or unwilling to comply with the study protocol&#xD;
                  patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nephrology Department- Hospital Universitari Bellvtge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>NURIA LLOBERAS BLANCH</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

